• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Arvinas Inc.

    6/27/24 5:03:11 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARVN alert in real time by email
    S-8 1 arvn-inducementgrantsx8jun.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 27, 2024
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    __________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    __________________
    ARVINAS, INC.
    (Exact Name of Registrant as Specified in Its Charter)
    __________________

    Delaware47-2566120
    (State or Other Jurisdiction of
    Incorporation or Organization)
    (I.R.S. Employer
    Identification No.)
    5 Science Park
    395 Winchester Ave.
    New Haven, Connecticut
    06511
    (Address of Principal Executive Offices)(Zip Code)

    Inducement Stock Option Award (June 2024)
    Inducement Restricted Stock Unit Award (June 2024)
    (Full Title of the Plans)
    John Houston, Ph.D.
    President and Chief Executive Officer
    Arvinas, Inc.
    5 Science Park
    395 Winchester Ave.
    New Haven, Connecticut 06511
    (Name and Address of Agent for Service)
    (203) 535-1456
    (Telephone Number, Including Area Code, of Agent for Service)
    __________________
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐





    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    Item 1. Plan Information.
    The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).
    Item 2. Registrant Information and Employee Plan Annual Information.
    The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference.
    The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:
    (a)    The registrant’s latest annual report filed pursuant to Section 13(a) or 15(d) of the Exchange Act or the latest prospectus filed pursuant to Rule 424(b) under the Securities Act that contains audited financial statements for the registrant’s latest fiscal year for which such statements have been filed;
    (b)    All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the document referred to in (a) above; and
    (c)    The description of the registrant’s common stock contained in the registrant’s registration statement on Form 8-A as filed with the Commission on September 21, 2018, as the description therein has been updated and superseded by the description of the registrant’s capital stock contained in Exhibit 4.4 to the registrant’s annual report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Commission on March 16, 2020, and including any amendments and reports filed for the purpose of updating such description.
    All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.



    Item 4. Description of Securities.
    Not applicable.
    Item 5. Interests of Named Experts and Counsel.
    Not applicable.
    Item 6. Indemnification of Directors and Officers.
    The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law (“DGCL”) and the registrant’s certificate of incorporation and bylaws.
    Section 102 of the DGCL permits a corporation to eliminate the personal liability of its directors or officers to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except (1) where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct, knowingly violated a law or obtained an improper personal benefit, (2) where any director authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law, or (3) for any officer, in any action by or in the right of the corporation. The registrant’s certificate of incorporation provides that no director shall be personally liable to the registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.
    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.
    The registrant’s certificate of incorporation provides that it will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the registrant) by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the registrant’s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The registrant’s certificate of incorporation also provides that it will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the registrant to procure a judgment in the registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the registrant’s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall



    have been adjudged to be liable to the registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
    The registrant has entered into indemnification agreements with all of its directors and executive officers. In general, these agreements provide that the registrant will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of the registrant or in connection with their service at the registrant’s request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer.
    The registrant maintains a general liability insurance policy which covers certain liabilities of the directors and officers of the registrant arising out of claims based on acts or omissions in their capacities as directors or officers.
    Item 7. Exemption from Registration Claimed.
    Not applicable.
    Item 8. Exhibits
    The following exhibits are incorporated herein by reference:
    Exhibit
    No.
    Description
    4.1 (1)
    Restated Certificate of Incorporation of the Registrant
    4.2 (2)
    Second Amended and Restated Bylaws of the Registrant
    5.1 *
    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant
    23.1 *
    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
    23.2 *
    Consent of Deloitte & Touche LLP, independent registered public accounting firm for the Registrant
    24.1 *
    Power of Attorney (included on the signature pages of this registration statement)
    99.1 (3)
    Form of Inducement Stock Option Award Agreement
    99.2 (4)
    Form of Inducement Restricted Stock Unit Award Agreement

    107 *
    Calculation of Filing Fee Tables

    (1)Previously filed with the Securities and Exchange Commission on October 1, 2018 as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) and incorporated herein by reference.
    (2)Previously filed with the Securities and Exchange Commission on June 21, 2023 as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) and incorporated herein by reference.
    (3)Previously filed with the Securities and Exchange Commission on January 16, 2024 as Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-276519) and incorporated herein by reference.
    (4)Previously filed with the Securities and Exchange Commission on January 16, 2024 as Exhibit 99.4 to the Registrant’s Registration Statement on Form S-8 (File No. 333-276519) and incorporated herein by reference.
    *Filed herewith
    Item 9. Undertakings.
    1.    The undersigned registrant hereby undertakes:



    (1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    (i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii)    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
    (2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    2.    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3.    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.





    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Haven, State of Connecticut, on this 27th day of June, 2024.
    ARVINAS, INC.
    By:/s/ John Houston, Ph.D.
    John Houston, Ph.D.
    President and Chief Executive Officer



    POWER OF ATTORNEY AND SIGNATURES
    We, the undersigned officers and directors of Arvinas, Inc., hereby severally constitute and appoint John Houston, Ph.D. and Andrew Saik, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 filed herewith and any and all amendments to said Registration Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Arvinas, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ John Houston, Ph.D.
    President, Chief Executive Officer and Chairman of the Board of Directors
     (principal executive officer)
    June 27, 2024
    John Houston, Ph.D.
    /s/ Andrew Saik
    Chief Financial Officer and Treasurer
    (principal financial officer)
    June 27, 2024
    Andrew Saik
    /s/ David Loomis
    Vice President and Chief Accounting Officer
    (principal accounting officer)
    June 27, 2024
    David Loomis
    /s/ Sunil Agarwal, M.D.Director
    June 27, 2024
    Sunil Agarwal, M.D.
    /s/ Linda BainDirector
    June 27, 2024
    Linda Bain
    /s/ Everett CunninghamDirector
    June 27, 2024
    Everett Cunningham
    /s/ Edward Kennedy, Jr.Director
    June 27, 2024
    Edward Kennedy, Jr.
    /s/ Briggs Morrison, M.D.Director
    June 27, 2024
    Briggs Morrison, M.D.
    /s/ Leslie Norwalk, Esq.Director
    June 27, 2024
    Leslie Norwalk, Esq.
    /s/ Laurie Smaldone Alsup, M.D.Director
    June 27, 2024
    Laurie Smaldone Alsup, M.D.
    /s/ John YoungDirector
    June 27, 2024
    John Young

    Get the next $ARVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARVN

    DatePrice TargetRatingAnalyst
    1/6/2026$15.00Neutral → Buy
    Citigroup
    10/15/2025$6.00Neutral → Sell
    Goldman
    9/24/2025$10.00Buy → Neutral
    BofA Securities
    9/17/2025$16.00Overweight
    Barclays
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    5/5/2025$11.00Buy → Hold
    Truist
    5/2/2025$10.00Buy → Hold
    Jefferies
    5/2/2025Buy → Hold
    TD Cowen
    More analyst ratings

    $ARVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

    – Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody, presented in a poster at the 67th American Society of Hematology (ASH®) Annual Meeting and Exposition, held December 6–9, 2025, in Orl

    12/6/25 8:05:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

    NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company's website. About Arvinas Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to improving the lives o

    11/26/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Loomis David K sold $2,275 worth of shares (230 units at $9.89), decreasing direct ownership by 0.72% to 31,697 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    11/7/25 4:20:24 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Morrison Briggs bought $227,010 worth of shares (30,000 units at $7.57), increasing direct ownership by 65% to 76,021 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    9/24/25 9:16:17 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agarwal Sunil was granted 16,025 shares, increasing direct ownership by 113% to 30,166 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    6/30/25 6:14:09 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Morrison Briggs bought $227,010 worth of shares (30,000 units at $7.57), increasing direct ownership by 65% to 76,021 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    9/24/25 9:16:17 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arvinas upgraded by Citigroup with a new price target

    Citigroup upgraded Arvinas from Neutral to Buy and set a new price target of $15.00

    1/6/26 8:21:48 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas downgraded by Goldman with a new price target

    Goldman downgraded Arvinas from Neutral to Sell and set a new price target of $6.00

    10/15/25 8:13:39 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas downgraded by BofA Securities with a new price target

    BofA Securities downgraded Arvinas from Buy to Neutral and set a new price target of $10.00

    9/24/25 7:54:47 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    SEC Filings

    View All

    Arvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ARVINAS, INC. (0001655759) (Filer)

    12/8/25 6:36:04 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Arvinas Inc.

    SCHEDULE 13G - ARVINAS, INC. (0001655759) (Subject)

    11/14/25 4:09:06 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.

    SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/25 4:08:17 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    Financials

    Live finance-specific insights

    View All

    Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    – Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a third party for the commercialization and potential further development of vepdegestrant – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Nov. 05, 2025 (GLOBE NEWSWIRE)

    11/5/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

    NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the third quarter of 2025 and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedic

    10/29/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with Parkinson's disease – – Presented preclinical data from ARV-393 program demonstrating single-agent activity and favorable combinability profile – – Initiated Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring KRAS G12D mutations – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology compan

    8/6/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

    – John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, an

    7/9/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

    7/30/24 7:00:00 AM ET
    $ARVN
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 1:22:38 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 7:00:23 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    9/10/24 10:30:07 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care